Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 12/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.45 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.44 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8065970 | 0.84 | ALPL (0.60) | ALPLERAP2ERAP1LMNAHPGD | |
| SCHEMBL8065976 | 0.84 | SLC6A2 (0.48) | ALPLLMNANPSR1 | |
| SCHEMBL8065979 | 0.77 | TTR (0.48) | ALPLLMNAHPGDNPSR1CYP2C9 | |
| SCHEMBL7354789 | 0.77 | XDH (0.59) | ALPLNOTUMLMNAHPGDMRGPRX4 | |
| SCHEMBL14317068 | 0.77 | MAPT (0.64) | ALPLNOTUMLMNANPSR1MRGPRX4 | |
| SCHEMBL14933935 | 0.77 | NOTUM (0.58) | ALPLNOTUMLMNAHPGDMRGPRX4 | |
| SCHEMBL8061095 | 0.77 | CYP2C9 (0.52) | LMNANPSR1CYP2C9 | |
| SCHEMBL7361708 | 0.76 | USP2 (0.60) | NOTUMLMNAHPGDNPSR1MRGPRX4 | |
| SCHEMBL4314290 | 0.76 | NOTUM (0.63) | ALPLNOTUMLMNAHPGDNPSR1 | |
| SCHEMBL15880442 | 0.76 | ALDH1A1 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617208-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617208-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2504003-B1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160081951-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20150336880-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2015-11-26 | — | — | US | disclosed |
| US-20150336880-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2015-11-26 | — | — | US | disclosed |
| US-9115064-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115064-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140194416-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194416-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20120258965-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-10-11 | — | — | US | disclosed |
| US-8227639-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227639-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2011063339-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063400-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20090163487-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2009-06-25 | — | — | US | disclosed |
| US-20090163487-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2009-06-25 | — | — | US | disclosed |
| WO-2009042970-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | JOHNS HOPKINS UNIVERSITY (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081951-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | NOS2, NOS3, NOS1 | ALPL 1351/4885NOTUM 1042/4885ERAP2 3307/4885 |
| US-20120258965-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, NME4 | ALPL 1429/4885NOTUM 2452/4885ERAP2 3453/4885 |
| US-20090163487-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, NME4 | ALPL 1429/4885NOTUM 2452/4885ERAP2 3453/4885 |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | NOS2, NOS3, NOS1 | ALPL 1268/4885NOTUM 1914/4885ERAP2 3101/4885 |
| US-20140194416-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, NME4 | ALPL 1429/4885NOTUM 2452/4885ERAP2 3453/4885 |
| US-20150336880-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, NME4 | ALPL 1429/4885NOTUM 2452/4885ERAP2 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.